Epiregulin enhances tumorigenicity by activating the ERK/MAPK pathway in glioblastoma

Louis, 2007, The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol, 114, 97, 10.1007/s00401-007-0243-4

Van Meir, 2010, Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma, CA Cancer J Clin, 60, 166, 10.3322/caac.20069

Mrugala, 2008, Mechanisms of disease: temozolomide and glioblastoma—look to the future, Nat Clin Pract Oncol, 5, 476, 10.1038/ncponc1155

Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330

Network TCGAR, 2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385

Phillips, 2006, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis, Cancer Cell, 9, 157, 10.1016/j.ccr.2006.02.019

Wick, 2011, Pathway inhibition: emerging molecular targets for treating glioblastoma, Neuro Oncol, 13, 566, 10.1093/neuonc/nor039

Reya, 2001, Stem cells, cancer, and cancer stem cells, Nature, 414, 105, 10.1038/35102167

Liu, 2013, The multiple roles for Sox2 in stem cell maintenance and tumorigenesis, Cell Signal, 25, 1264, 10.1016/j.cellsig.2013.02.013

Lathia, 2010, Integrin alpha 6 regulates glioblastoma stem cells, Cell Stem Cell, 6, 421, 10.1016/j.stem.2010.02.018

Ogden, 2008, Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas, Neurosurgery, 62, 505, 10.1227/01.neu.0000316019.28421.95

Read, 2009, Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma, Cancer Cell, 15, 135, 10.1016/j.ccr.2008.12.016

Son, 2009, SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma, Cell Stem Cell, 4, 440, 10.1016/j.stem.2009.03.003

Bao, 2008, Targeting cancer stem cells through L1CAM suppresses glioma growth, Cancer Res, 68, 6043, 10.1158/0008-5472.CAN-08-1079

Galli, 2004, Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma, Cancer Res, 64, 7011, 10.1158/0008-5472.CAN-04-1364

Singh, 2004, Identification of human brain tumour initiating cells, Nature, 432, 396, 10.1038/nature03128

Tabu, 2010, Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks, Mol Cancer, 9, 39, 10.1186/1476-4598-9-39

Brescia, 2012, Current strategies for identification of glioma stem cells: adequate or unsatisfactory?, J Oncol, 2012, 376894, 10.1155/2012/376894

Verhaak, 2010, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell, 17, 98, 10.1016/j.ccr.2009.12.020

Eltarhouny, 2008, Genes controlling spread of breast cancer to lung “gang of 4.”, Exp Oncol, 30, 91

Komurasaki, 1997, Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4, Oncogene, 15, 2841, 10.1038/sj.onc.1201458

Inatomi, 2006, Regulation of amphiregulin and epiregulin expression in human colonic subepithelial myofibroblasts, Int J Mol Med, 18, 497

Gupta, 2007, Mediators of vascular remodelling co-opted for sequential steps in lung metastasis, Nature, 446, 765, 10.1038/nature05760

Lee, 2004, Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage, Mol Cell Biol, 24, 8907, 10.1128/MCB.24.20.8907-8916.2004

Yun, 2012, Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers, Lab Invest, 92, 1033, 10.1038/labinvest.2012.61

Jin, 2011, EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction, Cancer Res, 71, 7125, 10.1158/0008-5472.CAN-11-1330

Mazzoleni, 2010, Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis, Cancer Res, 70, 7500, 10.1158/0008-5472.CAN-10-2353

Bleau, 2009, PTEN/PI3 K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells, Cell Stem Cell, 4, 226, 10.1016/j.stem.2009.01.007

Hambardzumyan, 2008, PI3 K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo, Genes Dev, 22, 436, 10.1101/gad.1627008

Zhu, 2013, Moesin is a glioma progression marker that induces proliferation and Wnt/beta-catenin pathway activation via interaction with CD44, Cancer Res, 73, 1142, 10.1158/0008-5472.CAN-12-1040

De Bacco, 2012, The MET oncogene is a functional marker of a glioblastoma stem cell subtype, Cancer Res, 72, 4537, 10.1158/0008-5472.CAN-11-3490

Guryanova, 2011, Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3, Cancer Cell, 19, 498, 10.1016/j.ccr.2011.03.004

Sherry, 2009, STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells, Stem Cells, 27, 2383, 10.1002/stem.185

Ikushima, 2009, Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors, Cell Stem Cell, 5, 504, 10.1016/j.stem.2009.08.018

Fassl, 2012, Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1, Oncogene, 31, 4698, 10.1038/onc.2011.615

Fan, 2010, NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts, Stem Cells, 28, 5, 10.1002/stem.254

Hinohara, 2012, ErbB receptor tyrosine kinase/NF-kappaB signaling controls mammosphere formation in human breast cancer, Proc Natl Acad Sci U S A, 109, 6584, 10.1073/pnas.1113271109

de Groot, 2008, Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma, J Neurooncol, 90, 89, 10.1007/s11060-008-9637-y

Peereboom, 2010, Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme, J Neurooncol, 98, 93, 10.1007/s11060-009-0067-2

Prados, 2009, Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma, J Clin Oncol, 27, 579, 10.1200/JCO.2008.18.9639

Reardon, 2010, Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma, J Neurooncol, 96, 219, 10.1007/s11060-009-9950-0

van den Bent, 2009, Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group study 26034, J Clin Oncol, 27, 1268, 10.1200/JCO.2008.17.5984

Thiessen, 2010, A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation, Cancer Chemother Pharmacol, 65, 353, 10.1007/s00280-009-1041-6

He, 1995, A eukaryotic transcriptional repressor with carboxypeptidase activity, Nature, 378, 92, 10.1038/378092a0

Ro, 1991, The C/EBP-binding region and adjacent sites regulate expression of the adipose P2 gene in human preadipocytes, Mol Cell Biol, 11, 2303, 10.1128/MCB.11.4.2303

Ladha, 2012, Identification of genomic targets of transcription factor Aebp1 and its role in survival of glioma cells, Mol Cancer Res, 10, 1039, 10.1158/1541-7786.MCR-11-0488

Akagi, 2003, Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation, Proc Natl Acad Sci U S A, 100, 13567, 10.1073/pnas.1834876100

Kohsaka, 2011, A population of BJ fibroblasts escaped from Ras-induced senescence susceptible to transformation, Biochem Biophys Res Commun, 410, 878, 10.1016/j.bbrc.2011.06.082